Although it is controversial whether GLT‐1/EAAT‐2 downregulation is the initiator of AD, its role as an amplifier of disease progression is widely supported, and targeting to enhance its function or reverse aberrant localization has emerged as a potential therapeutic strategy. The gene discussed is SLC1A2; the disease is Alzheimer disease.